International Journal of Clinical Pharmacology and Therapeutics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Venlafaxine aggravating interstitial pneumonia: A case report
Int J Clin Pharmacol Ther. 2023 Nov 16. doi: 10.5414/CP204459. Online ahead of print.ABSTRACTA 70-year-old male taking venlafaxine for depression developed interstitial pneumonia and was admitted with shortness of breath and dyspnea. A computed tomography (CT) chest scan showed diffuse multiple lung lesions in both lungs, suggesting interstitial changes with inflammation or exudation. Compared with the CT chest scan 1 month earlier, there were significant progresses and new findings. The clinical diagnosis was interstitial pneumonia with pulmonary infection. The patient had been treated with fluvoxamine 100 mg/day, duloxet...
Source: International Journal of Clinical Pharmacology and Therapeutics - November 16, 2023 Category: Drugs & Pharmacology Authors: Xia Wu Lutao Zhang Chuanping Wang Source Type: research

German longitudinal prescription database (LRx): Description of characteristics, use in pharmacoepidemiological research, and limitations
In conclusion, the German LRx database could be a key source of data for future pharmacoepidemiological studies.PMID:37969094 | DOI:10.5414/CP204485 (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - November 16, 2023 Category: Drugs & Pharmacology Authors: Karel Kostev Ying Wang Robert Singh Matthias Kalder Sven H Loosen Christoph Roderburg Marcel Konrad Louis Jacob Source Type: research

Monitoring of blood levels in patients administered CYP3A4 inhibitor during the maintenance phase of venetoclax administration
CONCLUSION: The risk of elevated venetoclax blood levels needs to be considered when initiating CYP3A4 inhibitors and reducing venetoclax dosage on the same day.PMID:37969095 | DOI:10.5414/CP204490 (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - November 16, 2023 Category: Drugs & Pharmacology Authors: Toshiki Kubo Shunsuke Matsuo Rintaro Sogawa Takeo Yasu Toshiaki Nagaie Sho Okamoto Shinya Kimura Chisato Shimanoe Source Type: research

Effect of pre-treatment of EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database
CONCLUSION: Although further analyses are required to confirm our findings, this study indicated that pre-treatment with EGFR-TKI might not increase the ILD risk after ICI treatment.PMID:37969096 | DOI:10.5414/CP204491 (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - November 16, 2023 Category: Drugs & Pharmacology Authors: Naoto Okada Hirofumi Hamano Kenta Yagi Takahiro Niimura Fuka Aizawa Mitsuhiro Goda Yoshito Zamami Takashi Kitahara Keisuke Ishizawa Source Type: research

Is compressed colchicine tablet superior to other colchicine preparations in patients with familial Mediterranean fever?
CONCLUSION: Compressed colchicine tablets were shown to be superior to other colchicine preparations and compressed colchicine tablets to be a useful treatment option before initiating biological agents in patients who were unresponsive to coated colchicine.PMID:37969097 | DOI:10.5414/CP204494 (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - November 16, 2023 Category: Drugs & Pharmacology Authors: İbrahim Vasi R ıza Can Kardaş Derya Y ıldırım Burcug ül Kaya Rahime Duran Hazan Karadeniz Asl ıhan Avanoğlu Güler Abdulsamet Erden Hamit K üçük Berna G öker Abdurrahman Tufan Mehmet Akif Öztürk Source Type: research

Predictors for non-attainment of meropenem target concentrations when treating infections in critically ill patients
CONCLUSION: In addition to the expected risk factors (age and dosage), ARC was a predictor for non-attainment of the target concentration. The risk of non-attainment of target concentrations increased with an increase in creatinine clearance. Attention should be given to ARC and creatinine clearance when administering meropenem by intravenous infusion.PMID:37969092 | DOI:10.5414/CP204412 (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - November 16, 2023 Category: Drugs & Pharmacology Authors: Shao Jun Zheng Yifan Xu Nai Dong Chen Jing Wen Hao Yubing Zhu Qiong Jie Source Type: research